Sun Pharmaceuticals has posted a growth of 36% in net profit for 3QFY02, compared to the corresponding period last fiscal. Sales has jumped by more than 25% to touch Rs 1,968 m. On a sequential basis however, revenues have remained flat. Operating margins increased by 160 basis points to 26.5%, which is amongst the best in the industry.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Diluted Earnings per share*
P/E (at current price)
The sales performance was fuelled by 33% growth in exports, particularly bulk exports. On the other hand, domestic sales also grew at a healthy rate of 23%, far outperforming industry growth rates. The growth in domestic market was on the back of aggressive launch of new products. Sun Pharma has launched 10 new products in last six months.
Sun Pharma recently informed that Caraco Pharma, its US subsidiary, has received a approval for manufacturing and marketing metformin in the US markets, which is a generic name for US$ 1.8 bn drug Glucophage. Over the last six months, Caraco has received 4 drug approvals and is targeting 5 more approvals by the end of the year.
The stock price of the company has moved up sharply after the company announced drug approvals for Caraco Pharma. Markets are expecting that the company would stick to its target of achieving breakeven in Caraco Pharma by the end of the current year. At Rs 642, the company trades at a P/E multiple of 16x annualised earnings for 3QFY02. The performance of Caraco and time taken for its turnaround would be the key valuation driver going forward.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407